ALK and non-small cell lung carcinoma: Some modern therapeutic schedules for brain-metastasized NSCLC have been emerging, such as Epidermal Growth Factor Receptor inhibitor therapy [3,4], Anaplastic Lymphoma kinase (ALK) inhibitor therapy [5,6], and immunotherapy [7,8].